Faivre-Chauvet A, Gestin J F, Mease R C, Sai-Maurel C, Thédrez P, Slinkin M, Meinken G E, Srivastava S C, Chatal J F
INSERM Unit 211, Nantes, France.
Nucl Med Biol. 1993 Aug;20(6):763-71. doi: 10.1016/0969-8051(93)90163-o.
The five linker-containing immunoconjugates described in the preceding paper were labeled with 111In and tested for their biodistribution, pharmacokinetics and immunoscintigraphic imaging properties in tumor-xenografted nude mice. The results were compared with DTPADA and CDTAMA for reference. Results showed that, for immunoscintigraphy, the derivatives in decreasing order of effectiveness were: aliphatic (tumor/liver > 4.5 and tumor/kidney > 6.5 at 96 h), thioether (tumor/liver > 3 and tumor/kidney > 1.2 at 24 h), ethylene glycol succinate (tumor/liver > 1.7 and tumor/kidney > 0.5 at 24 h) and disulfide (tumor/liver > 0.5 and tumor/kidney > 0.6 at 96 h). Pharmacokinetic results were complementary with those of the biodistribution studies and provide a basis for the study of in vivo metabolic mechanisms of linker-immunoconjugates. Indium-111-labeled linker-immunoconjugates appear promising for tumor imaging with better contrast than what is obtained with the use of the conventional 111In-DTPA dianhydride chelate.
前文所述的五种含连接子的免疫缀合物用铟-111进行标记,并在荷瘤裸鼠中测试其生物分布、药代动力学和免疫闪烁成像特性。将结果与二乙三胺五乙酸二酐(DTPADA)和环己二胺四乙酸单甲酰胺(CDTAMA)进行比较以供参考。结果表明,对于免疫闪烁成像,有效性从高到低的衍生物依次为:脂肪族(96小时时肿瘤/肝脏>4.5且肿瘤/肾脏>6.5)、硫醚(24小时时肿瘤/肝脏>3且肿瘤/肾脏>1.2)、乙二醇琥珀酸酯(24小时时肿瘤/肝脏>1.7且肿瘤/肾脏>0.5)和二硫键(96小时时肿瘤/肝脏>0.5且肿瘤/肾脏>0.6)。药代动力学结果与生物分布研究结果互补,为研究连接子-免疫缀合物的体内代谢机制提供了依据。铟-111标记的连接子-免疫缀合物在肿瘤成像方面似乎很有前景,其对比度优于使用传统的铟-111-二乙三胺五乙酸二酐螯合物所获得的对比度。